Dysoxylum binectariferum Hook.f (Meliaceae), a rich source of rohitukine

被引：38

作者：

Mohanakumara, Patel ^{[1
,2
]}

Sreejayan, Nambiar ^{[2
]}

Priti, Vaidayanathan ^{[2
,3
]}

Ramesha, Bheemanahally Thimmappa ^{[1
,2
]}

Ravikanth, Gudasalamani ^{[2
,3
]}

Ganeshaiah, Kotiganahalli Narayanagowda ^{[2
,3
,4
]}

Vasudeva, Ramesh ^{[5
]}

Mohan, John ^{[7
]}

Santhoshkumar, Thankayyan Retnabai ^{[7
]}

Mishra, Prabhu Dutt ^{[6
]}

Ram, Viswakarma ^{[6
,8
]}

Shaanker, Ramanan Uma ^{[1
,2
,3
]}

机构：

[1] Univ Agr Sci Bangalore, Dept Crop Physiol, Bangalore 560065, Karnataka, India

[2] Univ Agr Sci Bangalore, Sch Ecol & Conservat, Bangalore 560065, Karnataka, India

[3] Ashoka Trust Res Ecol & Environm, Srirampura 560064, Bengaluru, India

[4] Univ Agr Sci Bangalore, Dept Forestry & Environm Sci, Bangalore 560065, Karnataka, India

[5] Coll Forestry, Dept Forest Biol & Tree Improvement, Sirsi 581401, Karnataka, India

[6] Piramal Life Sci Ltd, Bombay 400063, Maharashtra, India

[7] Rajiv Gandhi Ctr Biotechnol, Trivandrum 695014, Kerala, India

[8] Indian Inst Integrat Med CSIR, Jammu 180001, India

来源：

FITOTERAPIA | 2010年 / 81卷 / 02期

关键词：

Dysoxylum binectariferum; Rohitukine; Anticancer activity; Flavopiridol; DEPENDENT KINASE INHIBITOR; FLAVOPIRIDOL; CANCER; TRIAL;

D O I：

10.1016/j.fitote.2009.08.010

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Rohitukine, a chromane alkaloid, is a precursor of flavopiridol, a promising anti-cancer compound. Currently in Phase III clinical trials, flavopiridol is a potent inhibitor of several cyclin-dependent kinases (CDKs). Rohitukine was first reported from Amoora rohituka (0.083% dry weight) followed by that in Dysoxylum binectariferum (0.9% dry weight), both belonging to the family Meliaceae. Here, we report incredibly high yields of rohitukine (7% dry weight) in trees of D. binectariferum from the Western Ghats, India. Crude extracts of the tree were found to be highly effective against ovarian and breast cancer lines tested. (C) 2009 Elsevier B.V. All rights reserved.

引用

页码：145 / 148

页数：4

共 23 条

[1] Inhibition of HIV-I replication by P-TEFb inhibitors DRB, seliciclib and flavopiridol correlates with release of free P-TEFb from the large, inactive form of the complex [J].

Biglione, Sebastian ;

Byers, Sarah A. ;

Price, Jason P. ;

Nguyen, Van Trung ;

Bensaude, Olivier ;

Price, David H. ;

Maury, Wendy .

RETROVIROLOGY, 2007, 4

[2]

Byrd JC, 2006, J CLIN ONCOL, V24, P6516

[3]

Carlson BA, 1996, CANCER RES, V56, P2973

[4] International collaboration in drug discovery and development from natural sources [J].

Cragg, GM ;

Newman, DJ .

PURE AND APPLIED CHEMISTRY, 2005, 77 (11) :1923-1942

[5]

da Rocha Adriana B., 2001, Current Opinion in Pharmacology, V1, P364

[6] Issues and progress with protein kinase inhibitors for cancer treatment [J].

Dancey, J ;

Sausville, EA .

NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (04) :296-313

[7] Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics [J].

Fischer, PM ;

Lane, DP .

CURRENT MEDICINAL CHEMISTRY, 2000, 7 (12) :1213-1245

[8]

HARMON AD, 1979, TETRAHEDRON LETT, P721, DOI 10.1016/S0040-4039(01)93556-7

[9] Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: A phase II trial in adults with poor-risk acute myelogenous leukemia [J].

Karp, Judith E. ;

Smith, B. Douglas ;

Levis, Mark J. ;

Gore, Steven D. ;

Greer, Jacqueline ;

Hattenburg, Catherine ;

Briel, Janet ;

Jones, Richard J. ;

Wright, John J. ;

Colevas, A. Dimitri .

CLINICAL CANCER RESEARCH, 2007, 13 (15) :4467-4473

[10] Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status [J].

Kelland, LR .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2000, 9 (12) :2903-2911

← 1 2 3 →